308 related articles for article (PubMed ID: 32974944)
1. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Cornell R; Hari P; Tang S; Biran N; Callander N; Chari A; Chhabra S; Fiala MA; Gahvari Z; Gandhi U; Godby K; Gupta R; Jagannath S; Jagosky M; Kang Y; Kansagra A; Kauffman M; Kodali S; Kumar SK; Lakshman A; Liedtke M; Lonial S; Ma X; Malek E; Mansour J; McGehee EF; Neppalli A; Paul B; Richardson P; Scott EC; Shacham S; Shah J; Siegel DS; Umyarova E; Usmani SZ; Varnado W; Vij R; Costa L
Am J Hematol; 2021 Jan; 96(1):E5-E8. PubMed ID: 32974944
[No Abstract] [Full Text] [Related]
2. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Delimpasi S; Mateos MV; Auner HW; Gavriatopoulou M; Dimopoulos MA; Quach H; Pylypenko H; Hájek R; Leleu X; Dolai TK; Sinha DK; Venner CP; Benjamin R; Garg MK; Doronin V; Levy Y; Moreau P; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
Am J Hematol; 2022 Mar; 97(3):E83-E86. PubMed ID: 34882831
[No Abstract] [Full Text] [Related]
3. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
4. Selinexor and dexamethasone in multiple myeloma.
Burki TK
Lancet Oncol; 2018 Mar; 19(3):e146. PubMed ID: 29429914
[No Abstract] [Full Text] [Related]
5. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
6. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
[TBL] [Abstract][Full Text] [Related]
7. Selinexor-dexamethasone for refractory multiple myeloma.
Stirrups R
Lancet Oncol; 2019 Oct; 20(10):e560. PubMed ID: 31477451
[No Abstract] [Full Text] [Related]
8. Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Sherbenou D; Stalker M; Forsberg P; Mark TM
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e630-e634. PubMed ID: 33863694
[No Abstract] [Full Text] [Related]
9. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
10. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
11. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
12. Selinexor for the treatment of multiple myeloma.
Podar K; Shah J; Chari A; Richardson PG; Jagannath S
Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
[No Abstract] [Full Text] [Related]
13. Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
Abid H; Wu JF; Abid MB
Eur J Cancer; 2021 Sep; 154():7-10. PubMed ID: 34217910
[No Abstract] [Full Text] [Related]
14. Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
Nishihori T; Baz R
Expert Opin Drug Saf; 2020 Feb; 19(2):113-115. PubMed ID: 31910353
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).
Waldschmidt JM; Keller A; Ihorst G; Grishina O; Müller S; Wider D; Frey AV; King K; Simon R; May A; Tassone P; Duyster J; Jung M; Raje N; Wäsch R; Engelhardt M
Haematologica; 2018 Oct; 103(10):e473-e479. PubMed ID: 29674494
[No Abstract] [Full Text] [Related]
16. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
17. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.
Manasanch EE; Jain P; Chen W; Oriabure O; Badillo M; Feng L; Berkova Z; Orlowski RZ; Wang M
Am J Hematol; 2020 Sep; 95(9):E232-E235. PubMed ID: 32390148
[No Abstract] [Full Text] [Related]
19. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB; Reece DE; Kukreti V; Mikhael JR; Chen C; Trudel S; Laumann K; Vohra H; Fonseca R; Bergsagel PL; Leis JF; Tiedemann R; Stewart AK
Br J Haematol; 2014 Nov; 167(4):563-5. PubMed ID: 24974945
[No Abstract] [Full Text] [Related]
20. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Spicka I; Ocio EM; Oakervee HE; Greil R; Banh RH; Huang SY; D'Rozario JM; Dimopoulos MA; Martínez S; Extremera S; Kahatt C; Alfaro V; Carella AM; Meuleman N; Hájek R; Symeonidis A; Min CK; Cannell P; Ludwig H; Sonneveld P; Mateos MV
Ann Hematol; 2019 Sep; 98(9):2139-2150. PubMed ID: 31240472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
